At the 44th Annual J.P. Morgan Healthcare Conference, Charles River Laboratories International, Inc. outlined a multi‐year growth plan centered on its integrated drug development services platform. CEO James C. Foster highlighted the company’s 10% compound annual revenue growth since 2019, driven by a 15% expansion in early‐stage discovery services and an 8% increase in preclinical toxicology volumes. Management reaffirmed full‐year adjusted EBITDA margin guidance of 33%–34% and projected mid‐single‐digit organic revenue growth for fiscal 2026, supported by four new biologics programs set to launch in Q2 and Q4. The presentation also noted a $200 million share repurchase authorization, of which $75 million has been deployed year‐to‐date.

Charles River announced an agreement to acquire BioSource Asia for $510 million in cash, subject to customary adjustments. BioSource Asia supplies approximately 50,000 cynomolgus monkeys annually for drug safety testing, representing nearly 20% of Charles River’s current non‐human primate needs. The deal is expected to close in the third quarter and to be accretive to adjusted EPS in the first 12 months post‐close. Charles River anticipates $25 million in annual cost synergies by year two through optimized breeding operations and integrated logistics. Management views the transaction as a strategic move to secure a reliable supply chain amid increasing global demand for toxicology models and to support the firm’s 2028 target of $6 billion in annual revenue.